...
search icon
nxtc-img

NextCure  Inc, Common Stock

NXTC

NSQ

$0.797

+$0.02

(2.57%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$21.79M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
6.14K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.79
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.76 L
$2.57 H
$0.797

About NextCure  Inc, Common Stock

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameNXTCSectorS&P500
1-Week Return-15.43%1.76%-2.37%
1-Month Return-27.96%0.33%-3.79%
3-Month Return-44.43%-8.58%-0.46%
6-Month Return-53.41%-4.26%3.58%
1-Year Return-32.35%1.27%22.47%
3-Year Return-85.8%5.33%25.17%
5-Year Return-98.5%38.09%77.46%
10-Year Return-96.09%102.29%188.42%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue6.35M22.38M---[{"date":"2019-12-31","value":28.36,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue34.22K46.55K4.30M4.48M3.68M[{"date":"2019-12-31","value":0.76,"profit":true},{"date":"2020-12-31","value":1.04,"profit":true},{"date":"2021-12-31","value":95.98,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":82.23,"profit":true}]
Gross Profit6.31M22.38M(4.30M)(4.48M)(3.68M)[{"date":"2019-12-31","value":28.21,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-19.22,"profit":false},{"date":"2022-12-31","value":-20.02,"profit":false},{"date":"2023-12-31","value":-16.46,"profit":false}]
Gross Margin99.46%100.00%(Infinity%)(Infinity%)(Infinity%)[{"date":"2019-12-31","value":99.46,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}]
Operating Expenses43.83M63.60M70.77M75.91M67.64M[{"date":"2019-12-31","value":57.74,"profit":true},{"date":"2020-12-31","value":83.79,"profit":true},{"date":"2021-12-31","value":93.22,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":89.1,"profit":true}]
Operating Income(37.48M)(41.23M)(70.77M)(75.91M)(67.64M)[{"date":"2019-12-31","value":-3748200000,"profit":false},{"date":"2020-12-31","value":-4122500000,"profit":false},{"date":"2021-12-31","value":-7076500000,"profit":false},{"date":"2022-12-31","value":-7590900000,"profit":false},{"date":"2023-12-31","value":-6763700000,"profit":false}]
Total Non-Operating Income/Expense-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Pre-Tax Income(33.74M)(36.60M)(69.39M)(74.73M)(62.72M)[{"date":"2019-12-31","value":-3373700000,"profit":false},{"date":"2020-12-31","value":-3660300000,"profit":false},{"date":"2021-12-31","value":-6938900000,"profit":false},{"date":"2022-12-31","value":-7473300000,"profit":false},{"date":"2023-12-31","value":-6272300000,"profit":false}]
Income Taxes(3.75M)(3.41M)6.96M(5.30M)-[{"date":"2019-12-31","value":-53.81,"profit":false},{"date":"2020-12-31","value":-49.04,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-76.16,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(33.74M)(36.60M)(69.39M)(74.73M)(65.56M)[{"date":"2019-12-31","value":-3373700000,"profit":false},{"date":"2020-12-31","value":-3660300000,"profit":false},{"date":"2021-12-31","value":-6938900000,"profit":false},{"date":"2022-12-31","value":-7473300000,"profit":false},{"date":"2023-12-31","value":-6555600000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(33.74M)(33.19M)(69.39M)(69.43M)(62.72M)[{"date":"2019-12-31","value":-3373700000,"profit":false},{"date":"2020-12-31","value":-3319000000,"profit":false},{"date":"2021-12-31","value":-6938900000,"profit":false},{"date":"2022-12-31","value":-6943300000,"profit":false},{"date":"2023-12-31","value":-6272300000,"profit":false}]
EPS (Diluted)(5.78)(1.33)(2.51)(2.69)(2.25)[{"date":"2019-12-31","value":-578,"profit":false},{"date":"2020-12-31","value":-133,"profit":false},{"date":"2021-12-31","value":-251,"profit":false},{"date":"2022-12-31","value":-269,"profit":false},{"date":"2023-12-31","value":-225,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

NXTC
Cash Ratio 8.68
Current Ratio 9.07

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

NXTC
ROA (LTM) -31.09%
ROE (LTM) -54.75%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

NXTC
Debt Ratio Lower is generally better. Negative is bad. 0.16
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.84

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

NXTC
Trailing PE NM
Forward PE NM
P/S (TTM) 9.52
P/B 0.30
Price/FCF NM
EV/R 1.62
EV/Ebitda 0.51

FAQs

What is NextCure  Inc share price today?

NextCure  Inc (NXTC) share price today is $0.797

Can Indians buy NextCure  Inc shares?

Yes, Indians can buy shares of NextCure  Inc (NXTC) on Vested. To buy NextCure  Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NXTC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of NextCure  Inc be purchased?

Yes, you can purchase fractional shares of NextCure  Inc (NXTC) via the Vested app. You can start investing in NextCure  Inc (NXTC) with a minimum investment of $1.

How to invest in NextCure  Inc shares from India?

You can invest in shares of NextCure  Inc (NXTC) via Vested in three simple steps:

  • Click on Sign Up or Invest in NXTC stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in NextCure  Inc shares
What is NextCure  Inc 52-week high and low stock price?

The 52-week high price of NextCure  Inc (NXTC) is $2.57. The 52-week low price of NextCure  Inc (NXTC) is $0.76.

What is NextCure  Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of NextCure  Inc (NXTC) is

What is NextCure  Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of NextCure  Inc (NXTC) is 0.30

What is NextCure  Inc dividend yield?

The dividend yield of NextCure  Inc (NXTC) is 0.00%

What is the Market Cap of NextCure  Inc?

The market capitalization of NextCure  Inc (NXTC) is $21.79M

What is NextCure  Inc’s stock symbol?

The stock symbol (or ticker) of NextCure  Inc is NXTC

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top